Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Market (“Nasdaq”). As of the Closing Date, the Shares, the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 9 contracts
Samples: Underwriting Agreement (Better Therapeutics, Inc.), Underwriting Agreement (Sonnet BioTherapeutics Holdings, Inc.), Underwriting Agreement (Synlogic, Inc.)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The the Nasdaq Capital Market (the “Nasdaq”). As of Except as set forth in the Closing DateRegistration Statement, the SharesTime of Sale Disclosure Package and the Final Prospectus, there is no action pending by the Company or, to the Company’s knowledge, the Warrant Shares and Nasdaq to delist the Pre-Funded Warrant Common Stock from the Nasdaq, nor has the Company received any notification that the Nasdaq is contemplating terminating such listing. When issued, the Shares will have been duly authorized for listing be listed on the Nasdaq.
Appears in 8 contracts
Samples: Underwriting Agreement (Avinger Inc), Underwriting Agreement (Avinger Inc), Underwriting Agreement (Avinger Inc)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Market (“Nasdaq”). As of the Closing Date, the Shares, the Pre-Funded Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 6 contracts
Samples: Underwriting Agreement (Brickell Biotech, Inc.), Underwriting Agreement (Brickell Biotech, Inc.), Underwriting Agreement (Brickell Biotech, Inc.)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The the Nasdaq Capital Market (“Nasdaq”). As of There is no action pending by the Closing DateCompany or, to the Company’s knowledge, Nasdaq to delist the Common Stock from Nasdaq, nor has the Company received any notification that Nasdaq is contemplating terminating such listing. When issued, the Shares, Shares and the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing be listed on Nasdaq.
Appears in 4 contracts
Samples: Underwriting Agreement (SenesTech, Inc.), Underwriting Agreement (SenesTech, Inc.), Underwriting Agreement (Biocept Inc)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The the Nasdaq Capital Market (the “Nasdaq”). As of Except as set forth in the Closing DateProspectus, there is no action pending by the Company or, to the Company’s knowledge, the SharesNasdaq to delist the Common Stock from the Nasdaq, nor has the Company received any notification that the Nasdaq is contemplating terminating such listing. When issued, the Warrant Shares and the Pre-Funded Warrant Conversion Shares will have been duly authorized for listing be listed on the Nasdaq.
Appears in 3 contracts
Samples: Underwriting Agreement (Real Goods Solar, Inc.), Underwriting Agreement (Real Goods Solar, Inc.), Underwriting Agreement (Real Goods Solar, Inc.)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Market (“Nasdaq”). As of the Closing Date, the Shares, the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 3 contracts
Samples: Underwriting Agreement (Brickell Biotech, Inc.), Underwriting Agreement (Brickell Biotech, Inc.), Underwriting Agreement (aTYR PHARMA INC)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The the Nasdaq Capital Global Market (“Nasdaq”). As of the Closing DateWhen issued, the Shares, the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing be listed on Nasdaq.
Appears in 2 contracts
Samples: Underwriting Agreement (ACM Research, Inc.), Underwriting Agreement (ACM Research, Inc.)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The the Nasdaq Capital Market (“Nasdaq”). As of the Closing DateWhen issued, the Shares, the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing be listed on Nasdaq.
Appears in 2 contracts
Samples: Underwriting Agreement (Asv Holdings, Inc.), Underwriting Agreement (A.S.V., LLC)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Market (“Nasdaq”). As of the each Closing Date, the Shares, the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 2 contracts
Samples: Underwriting Agreement (Bionano Genomics, Inc), Underwriting Agreement (Bionano Genomics, Inc)
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Market (“Nasdaq”). As of the Closing Date, the Shares, the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 1 contract
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Global Market (“Nasdaq”). As of the Closing Date, the Shares, the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 1 contract
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Market (“Nasdaq”). As of the Closing Date, the Shares, the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 1 contract
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Market (“Nasdaq”). As of the Closing Date, the Shares, Company shall not have been notified of any objection to the listing of the Shares and the Warrant Shares and the Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 1 contract
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The the Nasdaq Capital Global Market (“Nasdaq”). As of the Closing DateWhen issued, the Shares, the Warrant Shares and the Pre-Funded Warrant Offered Shares will have been duly authorized for listing be listed on Nasdaq. To the Company’s knowledge, it is in compliance with all applicable listing requirements Nasdaq.
Appears in 1 contract
Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on The Nasdaq Capital Market (“Nasdaq”). As of the Closing Date, the Shares, the Warrant Shares and the he Pre-Funded Warrant Shares will have been duly authorized for listing on Nasdaq.
Appears in 1 contract
Samples: Underwriting Agreement (Sonnet BioTherapeutics Holdings, Inc.)